Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Author: Avi Kapoor | April 11, 2024 08:46am

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Verve Therapeutics Inc (NASDAQ:VERV)

  • On April 2, Verve Therapeutics announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease. The treatment is supposed to permanently turn off a protein called PCSK9, which helps reduce blood cholesterol levels. The company’s stock fell around 44% over the past month and has a 52-week low of $7.36 .
  • RSI Value: 25.88
  • VERV Price Action: Shares of Verve Therapeutics fell 8.5% to close at $8.01 on Wednesday.

UnitedHealth Group Inc (NYSE:UNH)

  • On April 10, TD Cowen analyst Gary Taylor maintained UnitedHealth with a Buy and lowered the price target from $607 to $546.. The company’s stock fell around 8% over the past month. It has a 52-week low of $445.68.
  • RSI Value: 27.67
  • UNH Price Action: Shares of UnitedHealth fell 2.1% to close at $450.05 on Wednesday.

Gilead Sciences, Inc. (NASDAQ:GILD)

  • On April 8, Gilead Sciences said it will release its first quarter 2024 financial results and guidance on Thursday, April 25, 2024, after the closing bell.. The company’s stock fell around 10% over the past month and has a 52-week low of $68.06.
  • RSI Value: 27.43
  • GILD Price Action: Shares of Gilead Sciences fell 2.6% to close at $68.12 on Wednesday.

 

Check This Out: How To Earn $500 A Month From Citigroup Stock Ahead Of Q1 Earnings Report

  •  

 

Posted In: GILD UNH VERV

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist